Monitor for the final prospectus supplement to determine offering size, pricing, and dilution level. Given the OTC listing and small market cap ($6M), even a modest offering could result in significant near-term dilution. Assess whether the capital raise supports near-term clinical milestones for CLD-401.
Price Chart
Executive Summary
Calidi Biotherapeutics (CLDI) announced a proposed underwritten public offering of units consisting of common stock (or pre-funded warrants) and accompanying common warrants, with expected gross proceeds to be used for working capital and general corporate purposes. The offering includes a 45-day over-allotment option for up to 15% additional shares/warrants, but no specific size, price, or share count was disclosed. Given the lack of financial details and the dilutive nature of the offering, the impact is limited to signaling capital-raising intent.
Key Facts
- Calidi Biotherapeutics announced a proposed public offering of units (common stock or pre-funded warrants + common warrants).
- Offering is underwritten by Ladenburg Thalmann & Co. Inc.
- Company expects to grant underwriters a 45-day option to purchase up to 15% additional shares/warrants.
- Proceeds will be used for working capital and general corporate purposes.
- No specific offering size, price, or number of shares disclosed.
- Offering made under an effective shelf registration (Form S-3, filed Feb 7, 2025).
Financial Impact
Unknown — offering size and pricing not disclosed; potential dilution depends on final terms.
Risk Factors
- Potential for significant equity dilution depending on offering size and price.
- No assurance the offering will be completed due to market or other conditions.
- Company is pre-revenue with no approved products; dependent on capital markets for survival.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers